RecruitingNCT06458972

Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tongji Hospital
Principal Investigator
Dong Lingli, MD
Tongji Hospital
Enrollment
139 enrolled
Eligibility
18-70 years · All sexes
Timeline
20242024

Study locations (1)

Collaborators

Jingzhou Central Hospital · Wuhan Central Hospital · Xiangyang Central Hospital · Wuhan No.1 Hospital · China Three Gorges University, Yichang, China · Shanghai Zhongshan Hospital · The First People's Hospital of Jingzhou

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06458972 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials